Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
104 hedge funds and large institutions have $528M invested in Sio Gene Therapies Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 38 closing their positions.
119% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $4.62M
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
9% less funds holding
Funds holding: 114 → 104 (-10)
21% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 38
26% less capital invested
Capital invested by funds: $718M → $528M (-$190M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.9M |
| 2 |
BlackRock
New York
|
+$8.16M |
| 3 |
Morgan Stanley
New York
|
+$4.88M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.72M |
| 5 |
Millennium Management
New York
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$16M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.1M |
| 3 |
SCM
Sio Capital Management
New York
|
-$7.7M |
| 4 |
DM
Deerfield Management
New York
|
-$7.24M |
| 5 |
Primecap Management
Pasadena,
California
|
-$4.73M |
SIOX Hedge Fund Activity: Q4 2017 in Review
104 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2017, worth a combined $528M — down 26% from $718M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of SIOX and 30 opened new positions — a net loss of 8 holders — while 27 trimmed existing stakes and 29 added.
The largest buyer was Great Point Partners, adding an estimated $15.9M. The largest seller was PointState Capital, exiting entirely with an estimated $16M sold.
- 104 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2017, down from 114 in Q3 2017.
- Funds reported $528M of Sio Gene Therapies Inc. Common Stock stock for Q4 2017, down 26% quarter-over-quarter.
- 30 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2017 and 38 closed out, a net change of -8 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2017 was Great Point Partners, an estimated $15.9M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2017 was PointState Capital, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2017.